Thomas A. Abrams
0000-0003-3101-1573
Publication & Citation Trends
Most Cited Works
Publications
228 total
Phase II trial of cabozantinib in combination with nivolumab for advanced extrapancreatic neuroendocrine tumors (epNET).
Cited by 0
Semantic Scholar
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.
Cited by 1
Semantic Scholar
Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor OA
Cited by 15
Semantic Scholar
Abstract A001: An open label, phase II trial of ERK inhibition alone and in combination with autophagy inhibition in patients with metastatic cancreatic cancer
Cited by 1
Semantic Scholar
RAS/RAF co-mutation and ERBB2 copy number modulates HER2 heterogeneity and responsiveness to HER2-directed therapy in colorectal cancer.
Cited by 5
Semantic Scholar
Abstract B005: A phase 1 expansion cohort study evaluating the safety and efficacy of the CHK1 inhibitor LY2880070 with low-dose gemcitabine in metastatic pancreatic adenocarcinoma
Cited by 0
Semantic Scholar
Changing treatment patterns for hepatocellular carcinoma: A SEER-Medicare study.
Cited by 0
Semantic Scholar
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab OA
Cited by 2
Semantic Scholar
Research Topics
Colorectal Cancer Treatments and Studies
(75)
Pancreatic and Hepatic Oncology Research
(48)
Cancer Genomics and Diagnostics
(42)
Cholangiocarcinoma and Gallbladder Cancer Studies
(41)
Hepatocellular Carcinoma Treatment and Prognosis
(37)
Frequent Co-Authors
Affiliations
Pennington Biomedical Research Center
Brigham and Women's Hospital
Novartis (Switzerland)
Lahey Hospital and Medical Center
Beth Israel Deaconess Medical Center